Asia Pacific Acute Lung Injury Market Size and Competitive Analysis by 2028

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Asia Pacific Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others)

  • Report Code : TIPRE00025718
  • Category : Life Sciences
  • No. of Pages : 102
Buy Now

The APAC acute lung injury market is expected to grow from US$ 122.16 million in 2021 to US$ 174.61 million by 2028; it is estimated to grow at a CAGR of 5.2% from 2021 to 2028.

China, India, Japan, South Korea, and Australia are major economies in APAC. Technological advancements by market players is expected to fuel the market growth.  Manufacturers in the acute lung injury treatment market are focusing on the adoption of various strategies such as product innovation, product launches, and approvals, as well as R&D investment for advancements, along with inorganic strategies such as merger and acquisition and partnerships as their developmental strategies to maintain the competitive environment in the market. For instance, Faron Pharmaceuticals, Ltd. Is engaged in developing pharmacological treatments for ALI with the help of a consortium. The FP-1201-lyo treatment for acute lung injury is in the third phase of clinical trials and is anticipated to obtain authorization during the forecast period. Similarly, in November 2020, Novartis entered into an exclusive license with Mesoblast to manufacture, develop, and commercialize remestemcel-L to treat ARDS associated with COVID-19. Moreover, recent advances in understanding ALI pathophysiology have led to investigations of numerous potential pharmacologic treatments. In June 2020, Chimerix initiated a Phase II/III clinical trial to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with ALI due to COVID-19. Therefore, the introduction of advanced products is likely to revolutionize and offer opportunities for the growth of the APAC acute lung injury market.

In case of COVID-19, APAC is highly affected specially India. As of September 2021, the COVID-19 cases reached 56.5 million in APAC, according to the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA). COVID-19 infection has been a serious problem in the patients with acute lung injury. According to the clinical data of infected patients in Asia, radiologic evidence of lung edema is common and deserves clinical attention. Lung edema is a manifestation of acute lung injury (ALI) and may progress to hypoxemia and potentially acute respiratory distress syndrome (ARDS). Patients diagnosed with ARDS and ALI have poorer prognosis and potentially higher mortality. Although no effective treatment is formally approved for COVID-19 infection, support of ventilation with oxygen therapy and sometimes mechanical ventilation is often required. Treatment with systemic and/or local glucocorticoids might be helpful to alleviate the pulmonary inflammation and edema, which may decrease the development and/or consequences of ARDS. For instance, a study combining data from China and Italy indicated that 27% of highly infected COVID-19 patients required assisted ventilation and had a 21% death rate. As a result, the acute lung injury market in the region has seen great expansion due to the COVID-19 impact.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC acute lung injury market. The APAC acute lung injury market is expected to grow at a good CAGR during the forecast period.  
APAC acute lung injury market

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

APAC Acute Lung Injury Market Segmentation     
APAC Acute Lung Injury Market – By Therapy

  • Mechanical Ventilation
  • Fluid Management
  • Pharmacotherapy
  • Adjunctive Procedures

APAC Acute Lung Injury Market – By End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

APAC Acute Lung Injury Market, by Country

  • China 
  • Japan   
  • India
  • Australia
  • South Korea
  • Rest of APAC

APAC Acute Lung Injury Market - Companies Mentioned

  • Angion
  • GlaxoSmithKline Plc
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc
  • Windtree Therapeutics, Inc.

Asia Pacific Acute Lung Injury Report Scope

Report Attribute Details
Market size in 2021 US$ 122.16 Million
Market Size by 2028 US$ 174.61 Million
Global CAGR (2021 - 2028) 5.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Therapy
  • Mechanical Ventilation
  • Fluid Management
  • Pharmacotherapy
  • Adjunctive Procedures
By End User
  • Hospitals
  • Ambulatory Surgery Centers
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Angion
  • GlaxoSmithKline Plc
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc
  • Windtree Therapeutics, Inc.
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    asia-pacific-acute-lung-injury-market-report-deliverables-img1
    asia-pacific-acute-lung-injury-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    Asia Pacific Acute Lung Injury Market
    Connect With Expert
    1. Angion
    2. GlaxoSmithKline Plc
    3. ReAlta Life Sciences, Inc.
    4. Stemedica Cell Technologies, Inc
    5. Windtree Therapeutics, Inc.
    asia-pacific-acute-lung-injury-market-cagr